Kinomica to Present Research Abstract on a Multi-drug Biomarker Signature to Predict Best First-line Treatments for Acute Myeloid Leukemia (AML) at the 2024 ASCO Annual Meeting
Predicting patient response to first-line AML treatment using phosphoproteomic data from routine diagnosis samples
LONDON, May 29, 2024 /PRNewswire/ -- Kinomica Ltd., a developer of KScan® precision oncology diagnostics, today announces that it will be presenting data on a multi-drug biomarker signature for accurately predicting best first-line treatments in newly-diagnosed acute myeloid leukemia patients at the American Society of Clinical Oncology (ASCO) annual meeting, which will be held May 31 - June 4, in Chicago, IL.
"AML is a heterogeneous malignancy with poor prognosis. Several treatments are approved for AML, but clinical trials have shown that current stratification approaches to determine patients' eligibility produce false positives and negatives," said Arran Dokal PhD, CTO of Kinomica. "Here, we used phosphoproteomics to build signatures that accurately predict which of the approved therapies venetoclax plus azacitidine, intensive chemotherapy (IC), or IC plus midostaurin may be more efficacious for a given patient."
Details of the poster presentation are as follow:
Poster Title: Multi-drug algorithm to accurately predict best first-line treatments in newly-diagnosed acute myeloid leukemia (AML)
Presenter: Pedro Rodriguez Cutillas at Barts Cancer Institute
Authors: Pedro Rodriguez Cutillas([1]), Weronika E. Borek([5]), Josie A. Christopher([5]), Luis Veiga Nobre([5]), Amy Campbell([5]), Janet Kelsall([5]), Federico Pedicona([5]), Nazrath Nawaz([5] ) , David N. Perkins([5] ) , Pedro Moreno Cardoso([5] ) , Andrea Arruda([2]), Alexander Joseph Ambinder([3]), Sayantanee Dutta([4]), Paolo Gallipoli([1]), Heinz Sill([4]), Gabriel Ghiaur([3]), Mark D. Minden([2]), Andrew Williamson([5]), John G. Gribben([1]), Arran David Dokal([5] )
Organizations: ([1] )Barts Cancer Institute,( [2] )Princess Margaret Cancer Centre, ([3] )Johns Hopkins University, ([4] )Medical University of Graz, ([5] )Kinomica Ltd
Poster Session: Hematologic Malignancies--Leukemia, Myelodysplastic Syndromes, and Allotransplant
Session Date and Time: Monday June 3, 2024, 9:00 AM - 12:00 PM CDT
Poster Board Number: 84
Abstract Presentation Number: 6525
The Abstract is available on the ASCO online itinerary planner here.
About Kinomica
Kinomica is a developer of precision oncology diagnostics. The company has developed KScan®, a phosphoproteomic diagnostic platform to help clinicians better realize the full potential of precision medicine by predicting which of the drugs currently approved to treat a disease a particular patient will respond best to, thereby aiding clinical decision making. Learn more at www.kinomica.com and follow us on LinkedIn.
Logo - https://mma.prnewswire.com/media/2422786/4729421/Kinomica_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/kinomica-to-present-research-abstract-on-a-multi-drug-biomarker-signature-to-predict-best-first-line-treatments-for-acute-myeloid-leukemia-aml-at-the-2024-asco-annual-meeting-302157990.html
SOURCE Kinomica Ltd.
